Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Preliminary results
Director departure
Quarterly results
CC transcript
ANGIODYNAMICS INC (ANGO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance",
"Presentation"
07/12/2023 8-K Quarterly results
01/05/2023 8-K Quarterly results
10/06/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
04/07/2022 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance",
"Presentation"
01/06/2022 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance",
"Presentation"
07/13/2021 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results",
"Presentation"
01/07/2021 8-K Quarterly results
09/29/2020 8-K Quarterly results
07/16/2020 8-K Quarterly results
04/07/2020 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2020 Third Quarter Financial Results",
"Presentation"
01/07/2020 8-K Quarterly results
10/03/2019 8-K Quarterly results
07/10/2019 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results"
04/02/2019 8-K Quarterly results
Docs: "CONSOLIDATED INCOME STATEMENTS"
01/04/2019 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2019 Second Quarter Financial Results Fiscal 2019 Second Quarter Highlights"
09/27/2018 8-K Quarterly results
07/11/2018 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results"
03/29/2018 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results"
01/04/2018 8-K Quarterly results
09/28/2017 8-K Quarterly results
03/30/2017 8-K Form 8-K - Current report
01/06/2017 8-K Form 8-K - Current report
10/05/2016 8-K Form 8-K - Current report
04/07/2016 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2016 Third Quarter Results"
01/07/2016 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2016 Second Quarter Results"
10/08/2015 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2016 First Quarter Results"
07/17/2015 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2015 Fourth Quarter and Full Year Financial Results"
04/09/2015 8-K Quarterly results
Docs: "Q3 FY15 Financial Results Net sales of $86.6 million decreased 2% year over year from $88.2 million in last fiscal year’s third quarter. Sales were flat year-over-year on a constant currency basis and excluding the planned wind down of the supply agreement with Boston Scientific . The following sales comparisons exclude the BSC supply agreement. Peripheral Vascular net sales in the third quarter were $46.2 million, down 2% compared to $47.4 million in fiscal year 2014 third quarter. Vascular Access net sales were $26.4 million, a decrease of 3% from $27.3 million in the year ago quarter. Oncology/Surgery net sales of $13.1 million grew 9% over the $12 million in the prior year’s third quarter. Overall, net sales in the U.S. were down 2% year over year to $68.4 million from $69.8 million. I..."
01/08/2015 8-K Quarterly results
Docs: "AngioDynamics Reports 2015 Second Quarter Financial Results"
10/09/2014 8-K Quarterly results
Docs: "AngioDynamics Reports 2015 First Quarter Financial Results"
07/23/2014 8-K Quarterly results
Docs: "AngioDynamics Reports 2014 Fourth Quarter and Full Year Financial Results",
"Presentation"
04/09/2014 8-K Quarterly results
Docs: "AngioDynamics Reports Fiscal 2014 Third Quarter Financial Results ● Net sales increase 8% over prior year to $88.2 million ● GAAP income per share of $0.14; Non-GAAP adjusted net income, excluding amortization, of $0.16 per share ● Adjusted EBITDA of $14.6 million ● Company’s revenue guidance to $351 million- $355 million for FY14; Adjusted EPS, excluding amortization, of $0.60-$0.63 ALBANY, N.Y., – AngioDynamics , a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported financial results for the fiscal 2014 third quarter ended February 28, 2014. “Our strong top line performance marks the fourth consecutive quarter of improved sales results, reflecting continued market..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy